{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:40:45Z","timestamp":1654605645940},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"2","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In a pivotal phase I\/II trial, the investigational bispecific T-cell engaging antibody mosunetuzumab demonstrated high response rates, significantly bettering those historically seen with standard care in patients with relapsed\/refractory follicular lymphoma. Drug maker Genentech announced it will file for FDA approval of mosunetuzumab to treat this form of non-Hodgkin lymphoma.<\/jats:p>","DOI":"10.1158\/2159-8290.cd-nb2021-0408","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T14:30:11Z","timestamp":1639665011000},"page":"280-280","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific Antibody Takes Down FL"],"prefix":"10.1158","volume":"12","member":"1086","published-online":{"date-parts":[[2022,2,9]]},"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/12\/2\/280\/3035325\/280.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/12\/2\/280\/3035325\/280.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T12:20:00Z","timestamp":1654604400000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/12\/2\/280\/678498\/Bispecific-Antibody-Takes-Down-FLBispecific"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-nb2021-0408","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]}}}